Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news